Correlation between the Ki-67 proliferation index and response to radiation therapy in small cell lung cancer

Radiation Oncology

Table 1 Patient characteristics

Patient no.	Sex	Age (yrs)	cstage	Ki-67 (%)	Radiation therapy		Chemotherapy
Patient no.	Sex	Age (yrs)	cstage	Ki-67 (%)	Fraction dose	Total dose	Schedule	Regimen
1	M	69	IIIB	79.77	1.5Gy/fr bid	45Gy	Concurrent	Etoposide + carboplatin
2	M	70	IIA	92.13	1.5Gy/fr bid	45Gy	Neoadjuvant	Etoposide + cisplatin
3	M	80	IIIB	75.87	1.5Gy/fr bid	45Gy	Neoadjuvant	Etoposide + carboplatin
4	F	69	IIA	66.41	2Gy/fr	50Gy	None
5	M	68	IIIB	45.55	2Gy/fr	50Gy	Neoadjuvant	Etoposide + cisplatin
6	M	84	IIIB	74.84	2Gy/fr	60Gy	None
7	M	72	IIIA	92.51	2Gy/fr	60Gy	Neoadjuvant	Etoposide + cisplatin
8	M	59	IIIA	74.81	1.5Gy/fr bid	45Gy	Concurrent	Etoposide + cisplatin
9	M	67	IIIA	99.21	1.5Gy/fr bid	45Gy	Concurrent	Etoposide + carboplatin
10	M	66	IIIA	95.74	1.5Gy/fr bid	45Gy	Concurrent	Etoposide + cisplatin
11	M	59	IIIB	89.2	1.5Gy/fr bid	45Gy	Concurrent	Etoposide + cisplatin
12	M	70	IIA	75.34	1.5Gy/fr bid	45Gy	Concurrent	Etoposide + cisplatin
13	M	81	IIB	72.79	3Gy/fr	45Gy	None
14	F	74	IIIB	92.31	1.8Gy/fr	50.4Gy	Concurrent	Etoposide + cisplatin
15	F	78	IIIB	64.57	2Gy/fr	50Gy	Neoadjuvant	Etoposide + cisplatin
16	M	68	IIIB	78.02	2Gy/fr	50Gy	Neoadjuvant	Etoposide + cisplatin
17	M	69	IIIA	78.57	1.5Gy/fr bid	45Gy	Concurrent	Etoposide + cisplatin
18	M	73	IIIA	98.2	1.5Gy/fr bid	45Gy	Concurrent	Etoposide + cisplatin
19	F	74	IIIA	69.71	1.5Gy/fr bid	45Gy	Neoadjuvant	Etoposide + cisplatin

ISSN: 1748-717X